New study tracks how patients feel about their HS treatment
NCT ID NCT06785675
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how satisfied people with moderate to severe hidradenitis suppurativa (HS) are with a new medication called secukinumab, and how it affects their quality of life. About 48 adults in the UAE who are just starting secukinumab will fill out questionnaires over a short period. The goal is to understand real-world benefits beyond just symptom control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Al Ain Abu Dhabi, United Arab Emirates, United Arab Emirates
-
Novartis Investigative Site
Abu Dhabi, United Arab Emirates
-
Novartis Investigative Site
Ras al-Khaimah, United Arab Emirates
-
Novartis Investigative Site
Sharjah city, United Arab Emirates
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could childhood trauma fuel skin inflammation?
- Head-to-Head: which pill tames hidradenitis suppurativa best?
- Skin disease evolution under the microscope: a 17-Year look at what drives severity
- Could early treatment tame a painful skin condition?
- New pill shows promise for controlling painful skin condition in long-term trial
- New shot could ease painful skin condition